Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.